Categories: News

OliX Pharmaceuticals to Participate in BIO Partnering at JPM and Biotech Showcase 2022 Conferences

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SUWON, Republic of Korea., Jan. 03, 2022 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will hold one-on-one meetings at BIO Partnering at JPM from January 10-14, 2022. The Company’s management will also participate in Biotech Showcase 2022, being held virtually from January 10-12, 2022 and January 17-19, 2022.

Dong Ki Lee, Ph.D., Founder and Chief Executive Officer, Sun Woo Hong, Ph.D., Head of Research and Development, and June Park, Principal Scientist, will be available to discuss platform-based early discovery collaborations and licensing options for its RNAi therapeutic candidates, including OLX703A for hepatitis B, OLX702A for nonalcoholic steatohepatitis, OLX104C for androgenic alopecia, and other pipeline programs.

The events coincide with the annual J.P. Morgan Healthcare Conference, being held virtually, and offer various opportunities for licensing, collaboration, consulting and investment opportunities for life sciences companies.

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Learn more: https://www.olixpharma.com/eng/

Media Contact:

Jon Yu
ICR Westwicke
Phone: +1.475.395.5375
jon.yu@westwicke.com

Staff

Recent Posts

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

2 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

2 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

2 hours ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

2 hours ago

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation…

2 hours ago

Nixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic Support

Nixol introduces a new natural supplement in the United Kingdom to support metabolism, curb cravings,…

2 hours ago